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Aims: Epilepsy affects 0.5–1% of the world's population, and approximately a third of these patients are
refractory to current medication. Given their ability to proliferate, differentiate and regenerate tissues, stem
cells could restore neural circuits lost during the course of the disease and reestablish the physiological
excitability of neurons. This study veriﬁed the therapeutic potential of bone marrow mononuclear cells
(BMMCs) on seizure control and cognitive impairment caused by experimentally induced epilepsy.
Main methods: Status epilepticus (SE) was induced by lithium–pilocarpine injection and controlled with
diazepam 90 min after SE onset. Lithium–pilocarpine-treated rats were intravenously transplanted 22 days
after SE with BMMCs obtained from enhanced green ﬂuorescent protein (eGFP) transgenic C57BL/6 mice.
Control epileptic animals were given an equivalent volume of saline or ﬁbroblast injections. Animals were
video-monitored for the presence of spontaneous recurrent seizures prior to and following the cell
administration procedure. In addition, rats underwent cognitive evaluation using a Morris water maze.
Key ﬁndings: Our data show that BMMCs reduced the frequency of seizures and improved the learning and
long-term spatial memory impairments of epileptic rats. EGFP-positive cells were detected in the brains of
transplanted animals by PCR analysis.
Signiﬁcance: The positive behavioral effects observed in our study indicate that BMMCs could represent a
promising therapeutic option in the management of chronic temporal lobe epilepsy.
© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Epilepsy is a chronic neurological disorder that affects 0.5–1% of
the population worldwide (Engel, 2001; Sander and Shorvon, 1996).
The response to therapy in newly diagnosed cases is generally good,
but up to 30% of patients cannot achieve acceptable seizure control
despite adequate trials with potentially effective antiepileptic agents
(Loscher, 2002). In addition, there is the risk of a large number of
adverse effects, and surgical treatment is limited due to possible brain
function impairments.
Temporal lobe epilepsy (TLE) is the most frequent refractory form
of epilepsy in adult patients (Engel, 2001). Patients with TLE often
show extensive cell loss in temporal brain areas, especially in the
hippocampus; this characterizes mesial temporal sclerosis (MTS)-iências, Instituto do Cérebro
de do Sul (PUCRS), Avenida
ala 07, CEP 90619-900, Porto
33203312.
evier OA license.associated TLE. Themain physiopathological ﬁndings observed inMTS
are neuronal loss, reactive gliosis, mossy ﬁber sprouting, dendritic
injury and neurogenesis (Babb et al., 1991; Blumcke et al., 1999).
Several clinical observations suggest that epilepsy is more complex
than recurrent seizures alone and that progressive cognitive impair-
ment should be included in the sequelae of refractory TLE, particularly
when associated with hippocampal sclerosis (Hermann et al., 2002;
Hermann et al., 2006; Oyegbile et al., 2006; Oyegbile et al., 2004).
Intense neuronal loss is intimately related to EMT and chronic
epileptic activity (Blumcke et al., 1999; Blumcke et al., 1996). Thus,
the replacement of cells lost during the course of disease or the
replacement of physiological mediators produced by the cells may
represent effective strategies in the treatment of refractory epilepsy.
Transplanted stem cells could exert their effects not only by
transdifferentiating but also by other means such as cell fusion, the
release of trophic factors or cytokines, or even by activating
endogenous neural stem cells (Terada et al., 2002).
A number of cell transplantation strategies have been studied in
experimental models of epilepsy (Carpentino et al., 2008; Chu et al.,
2004; Gernert et al., 2002; Hattiangady et al., 2008; Huber et al., 2001;
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al., 2010; Zaman et al., 2000). Recently, Costa-Ferro et al. (2010)
showed that bone marrow mononuclear cells (BMMCs) can prevent
the development of chronic seizures, reduce neuronal loss, and
inﬂuence the reorganization of the hippocampal network in the acute
phase of experimental epilepsy.
However, the therapeutic potential of BMMCs in chronic epileptic
disorders remainsunknown.Toexplore this possibility,we transplanted
lithium–pilocarpine-treated rats with the mononuclear cell fraction of
the bone marrow of enhanced green ﬂuorescent protein (eGFP)
transgenic C57BL/6 mice and investigated its effects on seizure
frequencyandduration aswell as cognitive outcome in chronic epilepsy.
Material and methods
Animals
Seventy male Wistar rats (30 days old, 90–120 g) and 15
transgenic eGFP+ C57BL/6 mice (60 days old, 25–30 g) were used in
this study. All animals were kept under environmentally controlled
conditions (12-hour light/dark cycle; 22–24 °C) and were given free
access to food and water. This study was approved by the Animal Care
and Use Committee of Pontifícia Universidade Católica do Rio Grande
do Sul. A timeline of the drug administrations, treatments and tests of
animals is shown in Table 1.
Status epilepticus (SE)
Experimental SE was induced by lithium–pilocarpine injection
(127 mg/kg, i.p. and 60 mg/kg, i.p.; respectively) (Cavalheiro et al.,
1991; Turski et al., 1983). Animals were treated with 1 mg/kg
methyscopolamine prior to pilocarpine injection to reduce peripheral
cholinergic effects. The duration of SE was controlled with diazepam
(10 mg/kg, i.p.; 90 min after SE onset). Seizures were scored using the
Racine scale (Racine, 1972), and only animals that were scored grade
5 were included in this study. Control animals received saline instead
of pilocarpine.
BMMC and ﬁbroblast preparation
BMMCs were obtained from C57BL/6 mice expressing eGFP, which
was used as a reporter of transplanted cells (Okabe et al., 1997). Fresh
bonemarrowwas extracted fromhumeri, femora and tibiaewith a 26 G
needle containing heparin (10,000 U in 50 ml of DPBS). The material
was centrifuged at 400 ×g for 10 min. The cell pellet was resuspended
with Roswell Park Memorial Institute (RPMI-1640) medium and
fractionated on a density gradient generated by centrifugation at
400 ×g over a Ficoll-Paque solution (Histopaque 11191 Sigma Aldrich,
St. Louis,MO). Themononuclear fraction over the Ficoll-Paque layerwas
collected and washed twice with DPBS. Cell concentrations were
determined with a Neubauer-counting chamber, and the number of
viable cells was determined by Trypan Blue exclusion. For the detection
of surface antigen, BMMCs were incubated with conjugated antibodiesTable 1
Timeline of experimental procedures.
Day 1 Lithium administration
Day 2 Pilocarpine-induced SE
Days 15–21 Video-monitoring of SRS (Pre-T)
Day 22 BMMC, saline or ﬁbroblast administration
Day 23 Nested-PCR (24 h post-transplantation)
Days 23–29 Video-monitoring of SRS (Post-T1)
Days 30–37 Video-monitoring of SRS (Post-T2)
Day 36 Nested-PCR (2 weeks post-transplantation)
Days 38–45 Morris Water Maze task
Day 52 Nested-PCR (1 month post-transplantation)
Day 82 Nested-PCR (2 months post-transplantation)against CD34, CD11b, CD117, CD45 and Sca1. Labeled cells were
collected and analyzed using a FACSCalibur cytometer. To ensure a
cellular control for BMMCtransplantation,weusedﬁbroblasts thatwere
obtained from NIH-3T3 cells line (American Type Culture Collection —
ATCC no. CRL-1658™ Rockville, MD). Fibroblasts were cultured with
DMEMmedium (Sigma Aldrich, St. Louis, MO) supplemented with 10%
bovine fetal serum, penicillin (100 U/ml) and streptomycin (100 U/mL)
at 37 °C in a humid atmosphere containing 5% CO2. The culturemedium
was replaced every 3 days, and cells were split whenever they reached
70% conﬂuence. Cell viability was evaluated by Trypan Blue exclusion.
Transplantation of BMMCs or ﬁbroblasts
After 7 days of video-monitoring, surviving lithium–pilocarpine
animals that showed spontaneous recurrent seizures (SRS) were
divided into three groups: Pilo+Saline (lithium–pilocarpine-treated
rats receiving saline injection, n=8); Pilo+BMMC (lithium–pilocar-
pine-treated rats transplanted with BMMC, n=8) and Pilo+Fib
(lithium–pilocarpine-treated rats transplanted with ﬁbroblasts, n=7).
Control non-epileptic animals were assigned to the following groups:
Saline (saline-treated rats receiving saline injection in replacement of
both pilocarpine and BMMC, n=8) and Saline+BMMC (saline-treated
rats transplanted with BMMC, n=8). The BMMC or ﬁbroblast
suspensionwasprepared for transplantation in saline at a concentration
of 1×107 cells in 200 μL total volume. The cells or saline were
administered via tail vein injection 22 days after SE. An additional
cohort of eight epileptic animals were injected with BMMCs as
described above but were sacriﬁced 24 h, 2 weeks or 1 month after
transplantation, and brain samples were collected for PCR. Animals that
did not exhibit seizures during the ﬁrst 7 days of videomonitoringwere
not included in this study.
Monitoring of spontaneous recurrent seizures (SRS)
Beginning 15 days after SE, the surviving animals were video
monitored 12 h/day (6-h light cycle and 6-h dark cycle) for 7 days.
This period was called “Pre-transplant” (Pre-T). On the seventh day of
monitoring (22 days after SE), animals were given BMMCs, ﬁbroblasts
or saline. Monitoring was maintained for another 14 days after
transplantation. For data analysis, the post-transplant period was
divided into 2 sub-periods of 7 days each: “Post-transplant 1” (Post-
T1) and “Post-transplant 2” (Post-T2). Spontaneous seizures corre-
sponding to grade 5 according to Racine's scale were considered for
statistical analysis. The observer was blind to the treatment (Arida
et al., 1999).
Training in the spatial version of the Morris water maze (MWM)
The MWMwas used to test spatial memory after BMMC, ﬁbroblast
or saline administration (Bonini et al., 2007; Greggio et al., 2011;
Morris, 1984). Brieﬂy, training was carried out for ﬁve consecutive
days. Rats were trained for eight trials a day, during which the
platform location remained constant. Each trial consisted of a swim
followed by a 30-s stay on the escape platform. Animals were given
60 s to ﬁnd the submerged platform and were guided to it by the
experimenter when they were unable to ﬁnd it. Time spent to ﬁnd the
platform was deﬁned as escape latency. A randomly chosen start
position was used in each trial. On day 6, the platform was removed,
and long-term spatial memory was evaluated during a probe test. The
rats were allowed 60 s of free swimming. The latency to swim to the
location where the platform was previously located, the time spent in
the quadrant where the platform was previously located (training
quadrant) and the number of crossings over an imaginary annulus
centered at that location were measured and used as indicators of
memory retention. Swimming velocity was also analyzed.
Fig. 1. BMMCs reduce seizure frequency in lithium–pilocarpine-treated rats. (A) Seizure
frequency observed for Pilo, Pilo+BMMC and Pilo+Fib groups prior to (Pre-T) and
after cell transplantation: post-transplant 1 (Post-T1) and 2 (Post-T2). (B) Seizure
duration for Pilo, Pilo+BMMC and Pilo+Fib groups prior to (Pre-T) and after cell
transplantation: post-transplant 1 (Post-T1) and 2 (Post-T2). Data are presented as the
mean±S.D., n=8 per group. ***pb0.001, **pb0.01 vs. Pilo; #pb0.05, ###pb0.001 vs.
Pilo+Fib in Bonferroni post hoc test after two-way ANOVA.
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We performed PCR analysis to identify the presence of transplanted
BMMCs in the brains of transplanted animals. We used the forward
primer 5′-ttgaattcgccaccatggtgagc-3′ and the reverse primer 5′-
ttgaattcttacttgtacagctcgtcc-3′ complimentary to aneGFPDNA sequence,
and reampliﬁed with the forward primer 5′-gggcacaagctggagtaca-3′
and the reverse primer 5′-atgttgtggcggatcttga-3′ using a nested PCR
technique. Animals were sacriﬁced, and samples were collected 24 h,
2 weeks, and 1 and 2 months after BMMC transplantation. A positive
control sample (eGFP+ DNA extracted from C57BL/6-eGFP mice) and a
negative control (without any DNA) were assayed along with
experimental samples in every reaction. Ampliﬁed products were
detected by gel electrophoresis (2% agarose containing ethidium
bromide) and visualized under ultraviolet light (Okabe et al., 1997).
Statistical analysis
Data are presented asmeans±standard deviation (S.D.) ormeans±
standard error of the mean (S.E.M.) as indicated in the ﬁgure legends. A
two-way analysis of variance (ANOVA) followed by the Bonferroni post
hoc test was used to analyze SRS frequency and duration. Data obtained
in the MWM were analyzed using a two-way ANOVA followed by the
Bonferroni post hoc test or a one-way ANOVA followed by the
Newman–Keuls post hoc test. Analyses were performed using Prism-
Graph 5.0 software (Graph-Pad Software, San Diego, CA). A statistical
signiﬁcance level of α=0.05 and pb0.05 was applied to all tests.
Results
BMMC transplantation reduces SRS frequency but not duration in
chronic epileptic rats
All rats administered with pilocarpine developed SE (grade 5 in
Racine's Scale) with a mean latency of 23.24±7.15 min. Mortality
7 days after SE was approximately 30%. Six animals that did not
show SRS during the ﬁrst days of video-monitoring were excluded
from the study prior to cell treatment. To analyze whether BMMC
reduced the duration and frequency of seizures, we monitored
lithium–pilocarpine-treated rats for 21 days and computed the num-
ber and duration of behavioral features corresponding to Racine grade
5. We used the difference in SRS frequency and duration at pre- and
post-transplant periods to infer whether BMMC promoted functional
improvement.
We did not observe signiﬁcant differences in SRS frequency between
groups in the period prior to cell administration (Pilo 12.13±1.12, Pilo±
BMMC 12.25±1.03, Pilo+Fib 12.00±2.00). However, BMMC trans-
plantation reduced seizure frequency in chronic epileptic rats [F(2, 60)=
6.6, p=0.0002, Fig. 1A]. At Post-T1, Pilo+BMMC rats showed fewer
seizures (10.13±0.83) when compared to animals treated with saline
(12.5±1.19, pb0.01) or ﬁbroblasts (12.14±2.73, pb0.05) (Fig. 1A).
Interestingly, at Post-T2, Pilo+BMMC, rats presented even fewer
frequent seizures (8.50±0.53) when compared to saline (13±1.41) or
ﬁbroblast-treated rats (13.43±2.07, pb0.001 vs. Pilo and vs. Pilo+Fib).
Hence, we observed a gradual reduction in seizure frequency as the
Pilo+BMMC animals showed less SRS in Post-T2 than in Post-T1. Pilo
and Pilo+Fib groups were not signiﬁcantly different (Fig. 1A), and
for the duration of SRS, we did not observe signiﬁcant differences
among any of the groups [F(2, 60)=0.25, p=0.9083, Fig. 1B].
BMMCs reverse the cognitive deﬁcit associated with the
lithium–pilocarpine model in the MWM
To evaluate whether BMMCs can reverse the cognitive deﬁcits
associated with the lithium–pilocarpine model of epilepsy, we
employed a MWM massed training protocol (Bonini et al., 2007;Morris, 1984). We observed a signiﬁcant difference in the learning
performance among experimental groups in the 5-day training
session [F(3, 140)=0.98, p=0.47, Fig. 2A]. As expected, lithium–
pilocarpine-induced epilepsy impaired spatial memory acquisition in
the MWM. BMMC administration decreased escape latency in
lithium–pilocarpine treated animals. BMMCs did not affect the
performance of Saline+BMMC animals because we did not observe
any signiﬁcant difference in these animals compared to controls.
A 60-s probe test in the absence of the escape platform carried out
24 h after the last training session conﬁrmed that lithium–pilocarpine
impairs the acquisition of spatial memory and that BMMCs reverse
this effect. Lithium–pilocarpine-treated animals spent less time
swimming in the target quadrant (Fig. 2B, pb0.001), crossed the
imaginary annulus fewer times (Fig. 2C, pb0.001) and displayed
signiﬁcantly longer latencies to swim over the previous location of the
platform (Fig. 2D, pb0.01) when compared to the Saline group.
Conversely, during the probe test, Pilo+BMMC rats showed a
preference for the training quadrant (Fig. 2B, pb0.05 vs. Pilo).
Additionally, Pilo+BMMC rats crossed an imaginary annulus cen-
tered at the previous location of the escape platform more times than
Pilo animals (Fig. 2C, pb0.01), and they showed signiﬁcantly shorter
latencies to swim over the previous location of the escape platform
(Fig. 2D, pb0.01 vs. Pilo). In addition, the escape latency observed in
lithium–pilocarpine-treated rats transplanted with BMMC was com-
parable to that of the Saline and Saline+BMMC groups (Fig. 2D).
There was no signiﬁcant difference in swimming speed among the
experimental groups (data not shown). Unfortunately, Pilo+Fib
Fig. 2. BMMC administration improves spatial memory acquisition and retention in epileptic rats tested in the MWM task. (A) Mean escape latency during the 5 days of training in
the MWM for rats given lithium–pilocarpine, lithium–pilocarpine+BMMC, saline or saline+BMMC. Data are presented in blocks of eight trials as the mean±S.E.M., n=8 per
group. ***pb0.001, **pb0.01, *pb0.05 vs. Saline and #pb0.05; ###pb0.001 vs. Pilo+BMMC in Bonferroni post hoc test after two-way ANOVA. (B) Mean time spent in the target
quadrant (TQ) during a 60-s probe test carried out 24 h after the last MWM training session (pb0.0001). (C) Number of crossings over an imaginary annulus centered at the location
previously occupied by the escape platform during the probe test (pb0.0001). (D) Latency to swim over the previous location of the escape platform on the probe test (p=0.0021).
Data are presented as the mean±S.E.M., n=8 per group. ***pb0.001, **pb0.01, *pb0.05 vs. Saline and #pb0.05 vs. Pilo+BMMC. Newman–Keuls post hoc test after one-way
ANOVA.
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MWM task due to the constant occurrence of SRS.
EGFP was detected in samples obtained from the brains of
BMMC-transplanted animals
We employed a nested PCR analysis to verify whether eGFP DNA
from BMMCs could be detected in the brains of transplanted animals.
This analysis was performed to elucidate whether the observed
beneﬁcial behavioral effects were associated with the migration of
cells to the injured brain. Ampliﬁed eGFP DNA was found in the brain
of animals 24 h, 2 weeks and 1 month post-transplantation. At
2 months after transplantation, eGFP was no longer detected in
sampled brain tissue (Fig. 3).
Discussion
In the present study, we demonstrated that BMMC administration
to chronic epileptic rats decreases the frequency but not the duration
of SRS. We also showed that cell transplantation prevents the learningFig. 3. Representative nested-PCR analysis results for eGFP at 24 h, 2 weeks (2 w), 1 month (
lithium–pilocarpine-treated rats. Marker 100 bp (M); negative control without template D
mice.andmemory deterioration due to lithium–pilocarpine induced SE. The
positive outcomes observed in our study could be correlated to the
presence of transplanted cells into the injured epileptic brain. This is a
pioneering study providing behavioral evidence supporting cell-based
therapy for chronic epilepsy.
Because seizures are intimately associated with epilepsy, we
aimed to verify whether BMMCs reduce the frequency and/or
duration of recurrent generalized seizures in chronic epileptic rats.
Our results demonstrate that seizures were gradually reduced in Pilo
+BMMC rats compared to those receiving pilocarpine alone (Pilo
group) or ﬁbroblasts (Pilo+Fib). A number of approaches have been
tested using cell therapy in epilepsy models. Ruschenschmidt et al.
(2005) have demonstrated that embryonic stem cell-derived neurons
display characteristic properties of neurons when transplanted in the
hippocampi of chronic epileptic animals. The same grafting technique
using striatal precursors, adult neural stem cells or hippocampal stem
cells in an acute period of the disease reduced seizure frequency in
chronic epilepsy (Hattiangady et al., 2008; Jing et al., 2009; Shen et al.,
2010). Choosing a different method of administration, Chu et al.
(2004) evaluated the effects of intravenously injected neural stem/1 m), and 2 months (2 m) after cell transplantation in brain samples from transplanted
NA (Mix); positive control (PC) eGFP DNA extracted from eGFP+transgenic C57BL/6
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during the acute period of epilepsy. Twenty-eight to 35 days later,
only 13% of the animals showed SRS, with a marked reduction in
seizure frequency. More recently, Costa-Ferro et al. (2010) showed
that BMMCs intravenously injected in rats 24 h post-SE are able to
suppress early SRS, reducing epileptogenesis (Costa-Ferro et al.,
2010). In the mentioned study only 25% of the transplanted animals
had SRS 120 days after BMMC administration. In addition, the authors
also showed a protective effect on long-term potentiation (LTP). It
must be highlighted that in only one of these studies was cell
transplantation performed during chronic epilepsy (Ruschenschmidt
et al., 2005), and this study did not evaluate seizure frequency.
Compared to the literature, especially concerning the intravenous
administration of cells, we observed a less pronounced reduction in
SRS frequency in the present study. This could be due to the fact that,
in contrast to the above-mentioned works, we administered the cells
22 days after SE, which allowed us to analyze their effect on chronic
epilepsy. Considering that transplanted cells could have found very
different niches, it was expected that we would observe a less
dramatic reduction in SRS frequency. In a chronic epileptic rat,
transplanted cells would have to regenerate a more extensive
neuronal area to compensate for the cells lost during the course of
either SE or SRS. Conversely, in an acute epileptic brain, cells could
exert their action by preventing further neuronal death. Therefore,
other studies set out to verify the neuroprotective effect of stem cells
from different sources and their ability to prevent the development of
SRS, suppressing epileptogenesis. In contrast, our purpose was to
analyze the potential of BMMCs in healing an established epileptic
brain. Our results are relevant to stem cell transplants during the
chronic epileptic period. Because most patients that seek medical
attention have a seizure history, the chronic epilepsy period would be
the most suitable for translational cell therapy-based interventions.
In another set of experiments, we observed that BMMCs improved
cognitive deﬁcits in the MWM task. Cognitive deﬁcits are present in
experimental epileptic animals and inpatientswith TLE, probably due to
hippocampal cell loss (Detour et al., 2005;Hermannet al., 2006). For this
reason, we employed the spatial version of the MWM task to analyze
whether BMMCs reverse cognitive deﬁcits associatedwith epilepsy. It is
known that pilocarpine-treated epileptic rats display poor performance
on this task (Detour et al., 2005). We observed that epileptic animals
that received BMMCs performed better in the MWM, indicating that
transplanted cells have a palliative effect on the mnemonic impairment
associatedwith lithium–pilocarpine. Toourknowledge,noother studies
have used memory tasks to measure functional improvement or
preservation after cell therapy in epilepsy. Nonetheless, our results are
partially consistent with the data previously obtained by our group,
showing that BMMCs are able to preserve LTP, which is an electrophys-
iological correlate of memory (Costa-Ferro et al., 2010).
Here, we show that EGFP DNA from intravenously injected BMMCs
can be found in the epileptic brain 24 h, 2 weeks and 1 month post-
transplantation. However, 2 months after the BMMCs administration,
EGFP was no longer detected. In a previous study, we showed that the
number of cells that enter the epileptic brain after intravenous injection
is small. Nonetheless, the cells equally survive for as long as 120 days for
either allogenic or xenogenic transplantations (Costa-Ferro et al., 2010).
Thus, it is likely thatEGFP is undetectable2 monthsafter transplantation
because of the small number of cells that gain access to the brain rather
than because of an immunological response against xenotransplanted
cells. In addition, it can be assumed that the blood–brain barrier (BBB)
could limit the access of an increased number of cells to the injured
epileptic brain. However, recent data show that beneﬁcial effects
observed after permeation of the BBB do not seem to relate to the
grafting of an increased amount of cells –which were only sporadically
detected in either animals that received mannitol or not – but rather to
other mechanisms such as the up-regulation of neurotrophic factors
(Borlongan et al., 2004; Yasuhara et al., 2010).Our data also show that intravenously injected BMMCs from eGFP
transgenic mice enter the brain of epileptic rats, reduce SRS frequency
and facilitate spatial learning. However, themechanisms that underlie
these functional improvements remain unclear. The bone marrow is a
permanent source of stem cells (Korbling and Estrov, 2003). Several
studies have demonstrated that BMMCs grafted in the central nervous
system express microglial and neuronal markers (Brazelton et al.,
2000; Eglitis andMezey, 1997; Mezey et al., 2000). In addition, BMMC
transdifferentiation into neurons was observed in human tissue
(Cogle et al., 2004). However, it is possible that BMMCs could exert
their effects by mechanisms other than transdifferentiation. Consid-
ering that epilepsy has an important inﬂammatory component
(Vezzani and Granata, 2005), the modulation of this component by
stem cells could represent an important aspect in the mechanism of
stem cell transplantation (Louboutin et al., 2011; Ohtaki et al., 2008;
Park et al., 2009; Pluchino et al., 2005; Schwarting et al., 2008). On the
other hand, the transplanted cells could provide the epileptic brain
with a number of trophic factors (Borlongan et al., 2004). It has been
shown in the hippocampus of epileptic rats that trophic factors such
as ﬁbroblast growth factor 2 (FGF-2), brain-derived neurotrophic
factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) can
reduce epileptogenesis (Eves et al., 2001; Kanter-Schlifke et al., 2007;
Rao et al., 2006). Furthermore, growth factors that have been
identiﬁed in hematopoiesis and angiogenesis – such as erythropoietin
(EPO) and granulocyte colony-stimulating growth factor (G-CSF) –
are currently being re-considered as therapeutic agents in a number of
neurological diseases (Chu et al., 2008; Li et al., 2009a; Maurer et al.,
2008; Minnerup et al., 2008). Additionally, it must be noted that
chronic temporal lobe epilepsy is associated with decreased neuro-
genesis (Hattiangady et al., 2004), which can contribute to the
persistence of seizures and cognitive deﬁcits. Indeed, during chronic
epilepsy, the levels of several trophic factors that play a role in neural
stem cells proliferation decrease (Shetty et al., 2003). Thus, providing
the epileptic brain with a means to recover the process of neurogen-
esis (e.g. via stem cell administration) might be beneﬁcial in the
treatment of epilepsy.
Conclusion
Our study provides evidence that intravenously administered
BMMCs can reduce seizure frequency and ameliorate learning and
spatialmemory impairments in chronic epileptic rats.Here,we show for
the ﬁrst time that BMMCs have a therapeutic effect on chronic epilepsy
and on lost cognitive functions following cell transplantation. Further
studies to elucidate the mechanisms by which transplanted cells exert
their effects are needed. Nonetheless, the positive behavioral effects we
observed represent a step toward BMMC transplantation becoming an
option for the management of chronic epilepsy.
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